TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11354919
Drug: Topical penciclovir
Normalized name: penciclovir Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical penciclovir applied every 2 hours during waking hours
Study: 11354919
Drug: Topical acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical acyclovir applied every 2 hours during waking hours
Study: 8173850
Drug: TENS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS plus placebo drug
Study: 7487614
Drug: No systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No systemic antibiotics
Study: 31565730
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for fit patients
Study: 24660605
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus Xuebijing (XBJ) injection
Study: 15483085
Drug: Mifepristone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (40 mg daily)
Study: 15483085
Drug: Mifepristone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (40 mg daily) + hCG
Study: 15483085
Drug: Mifepristone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (40 mg daily) without hCG (P only)
Study: 15483085
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (GnRH agonists)
Study: 30535537
Drug: Octreotide SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide SC depot 10 mg q2w
Study: 30535537
Drug: Octreotide SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide SC depot 20 mg q4w
Study: 23261122
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (scaling and root planing, extraction of hopeless teeth, local-delivery antibiotics)
Study: 23261122
Drug: Control (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (treatment after 6 months)
Study: 18082778
Drug: Intraosseous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraosseous administration of morphine sulfate (5 mg bolus)
Study: 18082778
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of morphine sulfate (5 mg bolus)
Study: 2864484
Drug: Increased IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased IgG titres with CMV-specific IgM antibody
Study: 29543538
Drug: Saffron (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron (30 ml per day for 8 weeks)
Study: 28701674
Drug: Resveratrol 100mg
Normalized name: Grape Seed Extract 10mg, Resveratrol 100mg Oral tablet
DrugBank: Resveratrol (DB02709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 100mg daily for 12 weeks
Study: 18475166
Drug: 1-4 mg
Normalized name: buprenorphine 1.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-4 mg doxazosin (doxazosin group)
Study: 14521253
Drug: Propofol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2.5 mg/kg i.v.)
Study: 14521253
Drug: Sevoflurane (6%+50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane (6%+50% N2O+50% O2) by inhalation
Study: 12353420
Drug: Enalapril (ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (ACE inhibitor) intake for 1 year
Study: 21421506
Drug: Glucocorticoid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid treatment (short-term low-dose)
Study: 21421506
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (lamivudine and routine integrated treatment)
Study: 16192735
Drug: Intranasal 17beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal 17beta‐estradiol
Study: 16594908
Drug: Intensive lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive lipid-lowering therapy (niacin or lovastatin plus colestipol)
Study: 16594908
Drug: Conventional lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional lipid-lowering therapy (diet +/- colestipol)
Study: 12891467
Drug: Aprotinin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (1 million KIU) administered 15 minutes before delivery
Study: 10488974
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with 30 mg beta-carotene and 25,000 IU retinyl palmitate
Study: 1707218
Drug: Ofloxacin (OFLX)
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin (OFLX) 100 mg twice daily for 4 to 15 weeks in group A
Study: 1707218
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (group B) with no OFLX or other antibiotics
Study: 6182816
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy (hyposensitization) with partially purified timothy extract or two timothy major allergens
Study: 6182816
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not specified, but implied as no treatment or different treatment)
Study: 31127302
Drug: Multicomponent intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent intervention (MI): each student received a daily healthy meal along with educational actions
Study: 28662406
Drug: Eribulin in
Normalized name: eriBULin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin in combination with pertuzumab and trastuzumab
Study: 24206407
Drug: Ardeh 28
Normalized name: PETROLATUM 1 g in 85 g TOPICAL GEL [ELIZABETH ARDEN EIGHT HOUR LIP PROTECTANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ardeh 28 g/d (two tablespoons) for six weeks
Study: 18636232
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (IIT) alone
Study: 18636232
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy combined with metformin (IIT+MET)
Study: 11008354
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg od, Amoxycillin 750 mg tid, Omeprazole 20 mg (Group A)
Study: 11008354
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg od, Amoxycillin 750 mg tid, Omeprazole 40 mg (Group B)
Study: 3960427
Drug: Perioperative intravenous
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative intravenous cefamandole
Study: 29786471
Drug: EGCG+RES (epigallocatechin‐gallate
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG+RES (epigallocatechin‐gallate 282 mg/d, resveratrol 80 mg/d)
Study: 27174221
Drug: Integrative medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative medicine rehabilitation (IMR)
Study: 12887843
Drug: Iron syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron syrup (Group A)
Study: 7798613
Drug: Topical retinaldehyde
Normalized name: retinaldehyde
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical retinaldehyde
Study: 8574720
Drug: Zaldaride 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaldaride 20 mg four times daily
Study: 8574720
Drug: Zaldaride 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaldaride 2 x 20 mg as initial loading dose followed by three doses of 20 mg on the first day and four doses of 20 mg on the second day
Study: 8574720
Drug: Loperamide 2
Normalized name: loperamide 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide 2 x 2 mg loading dose followed by a flexible dosage of 2 mg after each unformed stool (maximum of 16 mg daily)
Study: 8574720
Drug: Zaldaride without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zaldaride without a loading dose
Study: 7084497
Drug: P vaginal
Normalized name: glycerin/polycarbophil/carbomer 934P VAGINAL GEL WITH PREFILLED APPLICATOR (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: P vaginal suppositories
Study: 29871066
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with standardized dermatophagoides farinae extracts for 1 year
Study: 16174589
Drug: Guliu capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guliu capsule (GLC) combined with 89Sr
Study: 11527250
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) at 1,600 microg/day or 800 microg/day + pranlukast (450 mg/day)
Study: 11527250
Drug: Pranlukast (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranlukast (450 mg/day) with BDP at 800 microg/day (group I)
Study: 11527250
Drug: Pranlukast (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranlukast (450 mg/day) with BDP at 1,600 microg/day (group II)
Study: 11527250
Drug: Pranlukast (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranlukast (450 mg/day) with BDP at 1,600 microg/day + 5 to 20 mg prednisolone (group III)
Study: 11527250
Drug: Pranlukast (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranlukast (450 mg/day) with BDP introduced within the first year of onset of asthma
Study: 9250457
Drug: Clamped hyperinsulinemic
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clamped hyperinsulinemic hypoglycemia (60 mU.m‐2.min‐1) at 2.8 mmol/l
Study: 9250457
Drug: Euglycemia at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycemia at 5.0 mmol/l
Study: 29085049
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment specified)
Study: 3307582
Drug: Subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin (initial dose of 15,000 U, adjusted thereafter)
Study: 3307582
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin (bolus injection of 5000 U, followed by an infusion of 1250 U/h, adjusted)
Study: 31483005
Drug: Increased monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Increased monthly availability of fruits at households
Study: 28395207
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I); 2 in-person sessions (20-40 min) and 2 telephone sessions (15-20 min)
Study: 22906565
Drug: Purified anthocyanin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified anthocyanin mixture (320 mg/d)
Study: 19290531
Drug: Erythromycin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (3 mg/kg per dose 4 times daily)
Study: 16681761
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day of indole-3-carbinol (I3C)
Study: 16681761
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day of indole-3-carbinol (I3C)
Study: 9427988
Drug: Echothiophate iodide
Normalized name: Echothiophate Iodide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echothiophate iodide eyedrops once daily for 4 months
Study: 8387885
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation therapy (HFX RT) to a total tumor dose of 64.80 Gy (treatment arm 1)
Study: 8387885
Drug: HFX RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFX RT to the same tumor dose with chemotherapy (CT) consisting of 100 mg of carboplatin, days 1 and 2, and 100 mg of etoposide (VP‐16), days 1‐3 (treatment arm 2)
Study: 8387885
Drug: HFX RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFX RT to the same tumor dose with CT consisting of 200 mg of CBCDA, days 1 and 2, and 100 mg of VP‐16, days 1‐5 (treatment arm 3)
Study: 27760995
Drug: L-leucine
Normalized name: L-Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-leucine
Study: 25911631
Drug: REHLOW (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: REHLOW (250 g carbohydrates in 400 mL of water)
Study: 25911631
Drug: REHFULL (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: REHFULL (same syrup plus water to match fluid losses, 3170 ± 190 mL)
Study: 19236457
Drug: Subcutaneous immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunoglobulin (SCIG)
Study: 9174311
Drug: Subcutaneous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous saline (control)
Study: 21500927
Drug: Concurrent cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent cognitive load during training and testing
Study: 21500927
Drug: Concurrent cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent cognitive load during training
Study: 17200103
Drug: Faith-based weight-loss
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faith-based weight-loss intervention (treatment group)
Study: 11106204
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg o.d. for 8 weeks
Study: 11106204
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg o.d. after placebo
Study: 2571726
Drug: Patients taking
Normalized name: Lamictal Blue (For Patients Taking Valproate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients taking beta-blocker medication
Study: 1056801
Drug: Chemotherapy (biweekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (biweekly methotrexate and monthly prednisone and vincristine)
Study: 28431010
Drug: BMS-936559 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-936559 (0.3 mg/kg)
Study: 22938002
Drug: Extreme day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extreme day cream (EXD)
Study: 22938002
Drug: Extreme night
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extreme night treatment (EXN)
Study: 22938002
Drug: Extreme preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extreme preparations (EXD and EXN)
Study: 17616840
Drug: Twice-weekly, group-based,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly, group-based, moderate-intensity walking program (n = 77)
Study: 17616840
Drug: Daily vitamin
Normalized name: Daily Vitamin Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily vitamin B pills (n = 78)
Study: 17616840
Drug: Placebo pills
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills (n = 74)
Study: 14687958
Drug: Standard drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard drug treatment
Study: 14687958
Drug: Enhanced drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced drug treatment (e.g. case management and added social services)
Study: 11120398
Drug: 0.2 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 microg/kg doses of pentagastrin
Study: 11120398
Drug: 0.4 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 microg/kg doses of pentagastrin
Study: 11120398
Drug: 0.6 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 microg/kg doses of pentagastrin
Study: 11120398
Drug: 0.8 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 microg/kg doses of pentagastrin
Study: 9830263
Drug: 2% butenafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% butenafine and 20% urea cream
Study: 2025524
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (cyclosporine, prednisone, azathioprine)
Study: 2025524
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (prednisone, azathioprine)
Study: 6113483
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin (0.075 IU/kg)
Study: 6113483
Drug: Intramuscular insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular insulin (0.075 IU/kg)
Study: 6113483
Drug: Intravenous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous insulin (0.075 IU/kg)
Study: 30621794
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive control training program (30 min daily, 5 days/week for 12 weeks)
Study: 28914250
Drug: Pit and
Normalized name: ZINC OXIDE 220 mg in 1 g TOPICAL STICK [Spit and Polish Mineral Face SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pit and fissure sealant placed without bonding agent (GROUP A)
Study: 28914250
Drug: Pit and
Normalized name: ZINC OXIDE 220 mg in 1 g TOPICAL STICK [Spit and Polish Mineral Face SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pit and fissure sealant placed following sixth generation bonding agent (ADPER PROMT) (GROUP B)
Study: 28914250
Drug: Pit and
Normalized name: ZINC OXIDE 220 mg in 1 g TOPICAL STICK [Spit and Polish Mineral Face SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pit and fissure sealant placed following seventh generation bonding agent (OPTIBOND) (GROUP C)
Study: 28914250
Drug: Pit and
Normalized name: ZINC OXIDE 220 mg in 1 g TOPICAL STICK [Spit and Polish Mineral Face SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pit and fissure sealant placed following eighth generation bonding agent (FUTURA BOND DUAL CURE) (GROUP D)
Study: 16282256
Drug: START program
Approvals — FDA: no, EMA: no, PMDA: no
Description: START program (short-term acute residential treatment)
Study: 15065964
Drug: Naltrexone 50
Normalized name: naltrexone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 50 mg, administered daily or targeted to high‐risk drinking situations
Study: 15065964
Drug: Targeted administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted administration of Naltrexone
Study: 15065964
Drug: Naltrexone (targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (targeted administration)
Study: 11557107
Drug: Cisplatin 120
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 120 mg/m(2), mitomycin C 8 mg/m(2), vindesine 3 mg/m(2) per cycle
Study: 11557107
Drug: Carboplatin 500
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin 500 mg/m(2), mitomycin C 8 mg/m(2), vindesine 3 mg/m(2) per cycle
Study: 3190969
Drug: Plain solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain solution (0.5% bupivacaine 3 ml)
Study: 3190969
Drug: Hyperbaric solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric solution (0.5% bupivacaine 3 ml)
Study: 29231315
Drug: Pinaverium bromide
Normalized name: pinaverium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinaverium bromide tablet (50 mg, 3 times a day for 6 weeks).
Study: 7647025
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral nicorandil
Study: 7647025
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oral nicorandil
Study: 18337343
Drug: AS +
Normalized name: GT-AS
DrugBank: GT-AS (DB17883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS + SP (single dose)
Study: 18337343
Drug: AS monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS monotherapy (5 days)
Study: 17181919
Drug: Collagen-PVP (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen-PVP (2 ml, 3.4 mg of collagen)
Study: 10632418
Drug: CC (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC (100 mg daily for 5 days)
Study: 10632418
Drug: CC (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC (100 mg daily for 5 days) plus ethinyl E2 (0.05 mg daily for 5 days)
Study: 9187782
Drug: 10 ml.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml.kg‐1 Ringer's Lactate solution over 20 min (preload group, n = 10)
Study: 9187782
Drug: No crystalloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No crystalloid infusion (no‐preload group, n = 10)
Study: 24611636
Drug: Whole grain
Normalized name: Whole grain barley
DrugBank: Barley (DB10506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole grain foods rich in lignans (30 g/d of breakfast cereals or biscuits, 80 g/d of whole grain pasta)
Study: 22235107
Drug: CHO group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO group (water with 50 g maltodextrine)
Study: 22235107
Drug: GLN group
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLN group (water with 50 g maltodextrine plus 40 g GLN)
Study: 17708711
Drug: Denosumab 6,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 6, 14, or 30 mg every 3 months
Study: 17708711
Drug: Denosumab 14,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 14, 60, 100, or 210 mg every 6 months
Study: 2510652
Drug: Diltiazem (D+)
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem (D+) group: 14 patients, receiving a loading dose of 0.3 mg/kg followed by a continuous IV infusion of 2 micrograms/kg/d, then orally (120-180 mg/d) throughout the study.
Study: 2510652
Drug: Control (D-)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (D-) group: 16 patients, no diltiazem treatment.
Study: 29916944
Drug: Anxiety symptoms
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anxiety symptoms (measured by validated self‐administered questionnaires)
Study: 27581434
Drug: Flexyn2a (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexyn2a (10 μg)
Study: 17169794
Drug: Very high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very high-dose methotrexate (33.6 g/m2)
Study: 17169794
Drug: Very high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very high-dose methotrexate (33.6 g/m2) with intensified systemic and intrathecal therapy
Study: 12668651
Drug: Sequential doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential doxorubicin (A) x 4 -> paclitaxel (T) x 4 -> cyclophosphamide (C) x 4 every 2 weeks with filgrastim